An investigator-initiated clinical trial of WP1122 in cancer patients
Latest Information Update: 09 Dec 2021
At a glance
- Drugs WP 1122 (Primary)
- Indications Cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Moleculin Biotech
- 01 Dec 2021 According to a moleculin biotech media release, this trial is intended to start in 2022.
- 10 Nov 2021 According to a moleculin biotech media release, the company plans to an IND in the US for the treatment of pancreatic cancer in H2 2021.
- 05 Jul 2021 New trial record